查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2004806

遺傳性血管性水腫治療市場：2026-2032年全球市場預測（依治療方法、藥物類別、給藥途徑、分銷管道和最終用戶分類）

Hereditary Angioedema Therapeutics Market by Treatment Type, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年遺傳性血管性水腫治療市場價值 407.7 億美元，預計到 2026 年將成長至 434.9 億美元，年複合成長率為 6.45%，到 2032 年將達到 631.5 億美元。

主要市場統計數據
基準年 2025 407.7億美元
預計年份：2026年 434.9億美元
預測年份 2032 631.5億美元
複合年成長率 (%) 6.45%

對重新定義遺傳性血管性水腫的管理和策略重點的臨床、商業性和監管趨勢進行了簡明扼要且綜合的概述。

遺傳性血管性水腫的特徵是陣發性、可能危及生命的水腫，由緩激肽介導的通路失調引起，至今仍是一個獨特的治療領域。臨床治療已從以醫院為中心的急性介入發展為持續性治療，強調快速按需治療，並結合積極的預防策略，以降低發作頻率和嚴重程度。新型標靶治療、不斷改進的給藥途徑以及不斷變化的醫療服務體系，正在影響臨床決策、與保險公司的談判以及病患的用藥依從性。

近年來，治療創新、給藥方法的改變以及證據的積累，是如何改變遺傳性血管性水腫的臨床路徑和商業性價值的提案？

過去十年間，藥物治療模式、醫療服務體系和患者期望都發生了翻天覆地的變化，所有這些都在重塑遺傳性血管性水腫的治療生態系統。治療創新已超越傳統的血漿替代療法，涵蓋了靶向生技藥品和旨在抑制激肽釋放酶活性或阻斷緩激肽訊號傳導的小分子化合物。這使得按需治療和持續預防性護理成為可能。這些進展在為臨床醫師提供新選擇的同時，也提高了在真實臨床實務中評估療效、耐受性和用藥依從性的門檻。

本研究評估了近期關稅政策調整對遺傳性血管性水腫治療的供應鏈、製造選擇、臨床管理和獲取途徑的連鎖反應。

貿易政策和關稅框架的調整會對依賴特殊原料的複雜生物製藥和治療藥物的供應鏈經濟、產品供應和策略採購決策產生重大影響。影響中間體、低溫運輸運輸和醫療設備配件的關稅變化會推高製造商的成本結構，並導致不同分銷管道的價格波動。為了因應這些變化，相關人員正在重新審視供應商多元化、區域製造地和庫存策略，以確保依賴時效性治療的患者能夠持續獲得醫療服務。

透過治療目標、藥理分類、給藥途徑、分銷管道和最終用戶護理環境來分析治療生態系統，以幫助進行策略規劃。

此治療領域的細分透過明確治療目標、藥理學、給藥途徑、通路和終端用戶環境，為商業性和臨床決策提供框架。根據治療類型，重點關注按需治療和預防策略。按需干預措施包括緩激肽受體拮抗劑、激肽釋放酶抑制劑、血漿來源的C1抑制劑和重組C1抑制劑，而預防策略包括單株抗體、口服小分子藥物和血漿來源的C1抑制劑。這種治療類型分類闡明了即時症狀控制和長期預防癲癇發作之間的治療權衡，有助於制定臨床治療方案和個人化治療計劃。

區域醫療保健系統、支付方流程和醫療保健服務模式如何導致美洲、歐洲、中東和非洲以及亞太地區出現不同的部署模式。

區域差異持續影響遺傳性血管性水腫治療的臨床實務模式、監管路徑、報銷模式和推廣速度。在美洲，成熟的專科醫療網路、強大的私人保險公司以及集中的專業中心正在加速新型預防藥物的引入，並支持與專科藥房的密切合作。區域臨床路徑強調快速、按需的就醫途徑，同時結合不斷擴大的居家預防項目，這既體現了患者的意願，也反映了醫療機構減少急診治療需求的獎勵。

本檢驗了創新和成熟公司如何透過協調臨床差異化、經銷夥伴和真實世界數據 (REW) 來確保永續的商業性競爭力。

在遺傳性血管性水腫領域，企業策略日益側重於差異化的臨床特徵、創新的給藥方法以及提供證據以支持支付方和醫療服務提供者的價值提案。在生物製藥領域擁有豐富經驗的成熟生物製藥公司傾向於利用規模經濟、一體化生產結構和現有商業網路來推出單株抗體和重組酶，而規模小規模的生物技術公司則專注於高度標靶化的作用機制、新型口服分子或可實現皮下或居家給藥的製劑改進。平台創新者與專業經銷商之間的策略合作十分普遍，這種合作將臨床差異化與在複雜供應鏈中執行的能力相結合。

透過協調臨床證據、分散式供應鏈、供應鏈彈性以及與支付方合作，加快部署速度並保持可及性的實用策略。

行業領導者應優先考慮整合式方法，將治療差異化與可操作的交付模式以及可靠的證據相結合。首先，投資縱向真實世界研究和病患報告結局 (PRO) 評估工具，以證明其不僅具有臨床療效，還能減少醫療保健使用並改善日常生活功能。這些數據資產有助於加強與支付方的合約談判，並建立引人入勝的故事，從而確保優先地位，即使臨床差異細微。其次，最佳化產品形式和支援服務，以實現分散式醫療。開發培訓模組、遠端醫療支援和家庭用藥清單可以減少採用障礙並提高用藥依從性。

一種透明的、混合的證據整合方法，結合臨床文獻、相關人員訪談、註冊登記和產業分析，以支持策略決策。

本分析所依據的研究結合了對同儕審查的臨床文獻、監管文件和指南的系統性回顧，以及對臨床、支付者和商業相關人員的專家訪談。資料提取優先考慮治療機制、給藥途徑、記錄的療效、安全訊號和醫療服務模式。研究整合了來自臨床註冊和匿名化理賠數據的真實世界信息，揭示了治療途徑和醫療服務地點的變化，而無需依賴專有的市場規模資料集。

本文總結了為什麼整合臨床創新、供應鏈韌性和真實世界證據對於將治療方面的進步轉化為永續的患者獲取途徑至關重要。

遺傳性血管性水腫的治療格局正處於一個轉折點，基於機制的創新、柔軟性的給藥方式以及新的循證範式正在融合，從而構建出差異化的治療路徑。臨床醫生現在擁有更廣泛的選擇，可以根據每位患者的個別需求量身定做干涉措施，在即時、按需的干涉與能夠改善生活品質的長期預防策略之間取得平衡。同時，商業性成功越來越依賴在對照試驗之外，透過真實世界的療效、減少對急性護理的依賴以及以患者為中心的結果來證明其價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療類型分類的遺傳性血管性水腫治療市場

  • 一經請求
    • 緩激肽受體拮抗劑
    • 激肽釋放酶抑制劑
    • 血漿來源的C1抑制劑
    • 重組C1抑制劑
  • 預防性治療
    • 單株抗體
    • 口服小分子化合物
    • 血漿來源的C1抑制劑

第9章：遺傳性血管性水腫治療市場：依藥物類別分類

  • 緩激肽受體拮抗劑
  • 激肽釋放酶抑制劑
  • 單株抗體
  • 血漿來源的C1抑制劑
  • 重組C1抑制劑

第10章：遺傳性血管性水腫療法市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第11章：遺傳性血管性水腫治療市場：依通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第12章：遺傳性血管性水腫治療市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第13章：遺傳性血管性水腫治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：遺傳性血管性水腫治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：遺傳性血管性水腫治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國遺傳性血管性水腫治療藥物市場

第17章：中國遺傳性血管性水腫治療藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Apellis Pharmaceuticals, Inc.
  • Attune Pharmaceuticals, Inc.
  • Biocryst Pharmaceuticals, Inc.
  • BioMarin Pharmaceutical Inc.
  • CSL Behring LLC
  • Ionis Pharmaceuticals, Inc.
  • KalVista Pharmaceuticals, Inc.
  • Novartis AG
  • Pharming Group NV
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-742BD517F714

The Hereditary Angioedema Therapeutics Market was valued at USD 40.77 billion in 2025 and is projected to grow to USD 43.49 billion in 2026, with a CAGR of 6.45%, reaching USD 63.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 40.77 billion
Estimated Year [2026] USD 43.49 billion
Forecast Year [2032] USD 63.15 billion
CAGR (%) 6.45%

A concise integrated overview of clinical, commercial, and regulatory dynamics that are redefining hereditary angioedema management and strategic priorities

Hereditary angioedema remains a distinct therapeutic area characterized by episodic, potentially life-threatening swelling driven by dysregulated bradykinin-mediated pathways. Clinical management has evolved from acute, hospital-centered interventions to a continuum that emphasizes rapid on-demand relief combined with proactive prophylactic strategies to reduce attack frequency and severity. The interplay between novel targeted therapies, evolving administration routes, and shifting care settings now shapes clinical decision-making, payer negotiations, and patient adherence patterns.

This executive summary synthesizes contemporary clinical, commercial, and regulatory dynamics that are reshaping how clinicians, manufacturers, and health systems approach hereditary angioedema. It highlights transformational therapeutic innovations, evaluates the ripple effects of recent trade policy adjustments, and distills segmentation and regional trends that influence go-to-market tactics. The goal is to provide decision-makers with a concise, integrated perspective that supports evidence-driven prioritization of investments, partnerships, and product positioning across both acute and preventive care pathways.

How recent therapeutic innovations, administration shifts, and evidence generation are collectively transforming clinical pathways and commercial value propositions in hereditary angioedema

The past decade has witnessed transformative shifts across drug modalities, care delivery, and patient expectations that are converging to reshape the hereditary angioedema ecosystem. Therapeutic innovation has progressed beyond traditional plasma-derived replacement approaches to include targeted biologics and small molecules designed to interrupt kallikrein activity or block bradykinin signaling, enabling both efficacious on-demand relief and sustained prophylaxis. These advances have introduced new choices for clinicians, but they have also raised the bar for demonstrating comparative effectiveness, tolerability, and real-world adherence.

Concurrently, patient-centric delivery innovations-such as oral prophylactic agents and subcutaneous formulations-have accelerated the movement of care from inpatient settings into clinics and home environments. This decentralization increases the importance of patient education, remote monitoring, and support programs that ensure correct administration and timely escalation of care during breakthrough attacks. Payers and health systems now demand robust value narratives that combine clinical outcomes with evidence of reduced acute care utilization. As a result, manufacturers are investing in longitudinal evidence generation, patient-reported outcomes, and economic modeling to substantiate therapeutic differentiators and to support formulary positioning.

Finally, collaborative pathways between academic centers, specialty pharmacies, and advocacy groups are amplifying real-world data capture and enabling pragmatic comparative analyses. Innovations in registry design, digital symptom tracking, and pharmacovigilance are creating richer evidence streams that inform treatment sequencing and guideline evolution. Taken together, these shifts signal a maturing therapeutic landscape where scientific innovation is tightly linked to delivery model redesign and value demonstration.

Assessing how recent tariff policy adjustments can ripple through supply chains, manufacturing choices, clinical administration, and access pathways for hereditary angioedema treatments

The introduction of adjustment in trade policy and tariff frameworks can materially influence supply chain economics, product availability, and strategic sourcing decisions for therapeutics that rely on complex biologic production or specialized raw materials. Tariff changes affecting intermediate components, cold-chain transport, and medical device accessories elevate cost structures for manufacturers and can introduce variability in pricing across distribution channels. Anticipating such shifts, stakeholders are reevaluating supplier diversification, regional manufacturing footprints, and inventory strategies to preserve continuity of care for patients dependent on time-sensitive therapies.

Manufacturers that source critical inputs internationally may respond by regionalizing production or establishing contingency inventory hubs to mitigate the operational impact of tariff-driven cost pressures. These actions, while stabilizing supply, require capital allocation and lead-time adjustments that influence product launch sequencing and contracting negotiations with payers and providers. For clinically administered treatments, increased logistics complexity can also affect hospital and clinic procurement practices, leading institutions to favor therapies with simpler storage and handling requirements when clinically appropriate.

Moreover, tariffs can indirectly shape competitive dynamics by altering total delivered cost across routes of administration. For example, therapies that reduce dependence on intravenous administration and complex hospital services may present an advantage in environments where tariffs elevate the cost of imported infusion-related components. In parallel, specialty pharmacies and home care providers will need to adapt their procurement and reimbursement strategies to reflect any incremental cost burdens, working with manufacturers and payers to preserve patient access while maintaining sustainable margins. Ultimately, productive engagement between industry, policy stakeholders, and supply chain partners will be essential to navigate tariff-driven disruptions and to safeguard stable access to lifesaving therapeutics.

Deconstructing the therapeutic ecosystem through treatment intent, pharmacologic class, administration routes, distribution channels, and end-user care settings to inform strategy

Segmentation in this therapeutic area frames commercial and clinical decision-making by delineating treatment intent, pharmacology, administration route, distribution pathways, and end-user environments. Based on treatment type, emphasis is placed on both On Demand interventions and Prophylaxis strategies; On Demand interventions include bradykinin receptor antagonists, kallikrein inhibitors, plasma derived C1 inhibitors, and recombinant C1 inhibitors, while Prophylaxis strategies encompass monoclonal antibodies, oral small molecules, and plasma derived C1 inhibitors. This treatment-type taxonomy clarifies the therapeutic trade-offs between immediate symptomatic control and long-term attack prevention, informing clinical sequencing and patient-tailored regimens.

Based on drug class, analyzers consider bradykinin receptor antagonists, kallikrein inhibitors, monoclonal antibodies, plasma derived C1 inhibitors, and recombinant C1 inhibitors as distinct mechanisms with different safety profiles, administration requirements, and evidence expectations. These pharmacologic categorizations drive differential value messages to payers and clinicians, particularly when head-to-head comparative evidence remains limited. Based on route of administration, distinctions among intravenous, oral, and subcutaneous formats materially influence site-of-care economics, patient adherence, and design of support services, since intravenous therapies often require facility-based delivery whereas oral and subcutaneous options facilitate clinic or home administration.

Distribution channel segmentation further shapes commercial execution and access pathways, with hospital pharmacies, retail pharmacies, and specialty pharmacies each playing specific roles in dispensing, reimbursement navigation, and patient support. Hospital pharmacies remain central for acute administration and inpatient management, retail pharmacies provide convenience for routine refills and community access, and specialty pharmacies deliver care coordination and claims expertise for high-cost or complex therapies. Finally, end-user segmentation across clinic, home care, and hospital settings underscores the growing importance of decentralized care models, where home infusion or self-administered prophylaxis requires robust training, monitoring, and safety net arrangements to preserve clinical outcomes and patient confidence.

How regional healthcare architectures, payer processes, and care delivery models drive differentiated adoption patterns across the Americas, EMEA, and Asia-Pacific

Geography continues to shape clinical practice patterns, regulatory pathways, reimbursement models, and adoption velocity across hereditary angioedema therapeutics. In the Americas, established specialty care networks, a strong private-sector payer presence, and concentrated centers of expertise often accelerate uptake of novel prophylactic agents and support robust specialty pharmacy integration. Clinical pathways in this region emphasize rapid on-demand access paired with growing home-based prophylaxis programs, reflecting both patient preference and system incentives to reduce acute care utilization.

In Europe, Middle East & Africa, heterogeneity in national health system structures, access criteria, and procurement mechanisms results in variable adoption timelines. Countries with centralized health technology assessment processes commonly require comprehensive evidence packages that demonstrate real-world effectiveness and cost implications, while other jurisdictions may prioritize managed access arrangements or named-patient programs to bridge access during evidence development. Across these markets, clinician networks and regional centers of excellence play a pivotal role in shaping guideline interpretation and treatment sequencing.

Asia-Pacific presents a diverse landscape where regulatory modernization, expanding specialty care capacity, and rising patient advocacy are accelerating interest in both on-demand and prophylactic options. In several markets, the growth of outpatient infusion centers, specialty pharmacy capabilities, and digital health platforms is enabling broader adoption of self-administration approaches. Across all regions, cross-border collaborations, multinational clinical registries, and real-world evidence platforms are increasing the comparability of outcomes and informing multinational market entry strategies and value demonstration efforts.

Examining how innovators and incumbents align clinical differentiation, distribution partnerships, and real-world evidence to secure durable commercial advantage

Company strategies in hereditary angioedema increasingly center on differentiated clinical profiles, delivery innovations, and evidence generation that supports payer and provider value propositions. Established biopharmaceutical companies with experience in biologics tend to leverage scale, integrated manufacturing, and existing commercial networks to introduce monoclonal antibodies and recombinant enzymes, while smaller biotechnology firms focus on highly targeted mechanisms, novel oral molecules, or formulation improvements that enable subcutaneous use and home administration. Strategic partnerships between platform innovators and specialty distributors are common, as they combine clinical differentiation with execution capabilities across complex supply chains.

Commercial playbooks emphasize curated patient journeys, including adherence support, nurse-led training for self-administration, and outcomes tracking that can validate therapeutic benefits in routine practice. Companies are also prioritizing lifecycle management initiatives-such as new formulations, label expansions, and pediatric data generation-to extend clinical utility and address underserved subpopulations. In competitive landscapes where multiple classes coexist, successful firms articulate clear comparative hypotheses and invest in head-to-head or pragmatic registries to substantiate real-world advantages. Finally, manufacturing resilience and supply chain transparency are treated as strategic differentiators, particularly for therapies requiring cold chain logistics or plasma-derived inputs.

Actionable tactics for aligning clinical evidence, decentralized delivery, supply chain resilience, and payer engagement to accelerate adoption and sustain access

Industry leaders should prioritize an integrated approach that aligns therapeutic differentiation with pragmatic delivery models and robust evidence generation. First, invest in longitudinal real-world studies and patient-reported outcome instruments to demonstrate not only clinical efficacy but also reductions in healthcare utilization and improvements in daily functioning. These data assets strengthen contracting conversations with payers and create a defensible narrative for preferential placement when clinical differences are nuanced. Second, optimize product formats and support services to enable decentralization of care-developing training modules, telehealth support, and home administration checklists will reduce barriers to adoption and improve adherence.

Third, proactively assess supply chain exposure to tariff shifts and consider regional manufacturing or inventory buffering for critical components to preserve continuity of care. Engaging early with logistics partners and integrating scenario planning into commercial launch timelines will mitigate disruption risk. Fourth, establish targeted payer engagement strategies that map value stories to specific distribution channels and end-user contexts; specialty pharmacies and hospital procurement teams require differentiated evidence and operational assurances to endorse new therapies. Finally, pursue collaborative research with centers of excellence and patient advocacy organizations to accelerate enrollment in registries and to refine outcome measures that matter most to patients and payers, reinforcing both clinical and commercial positioning.

A transparent mixed-methods evidence synthesis combining clinical literature, stakeholder interviews, registries, and trade analyses to support strategic decision-making

The research underpinning this analysis combined a structured review of peer-reviewed clinical literature, regulatory documents, and guidelines with expert interviews across clinical, payer, and commercial stakeholders. Data abstraction prioritized therapeutic mechanism, administration route, documented outcomes, safety signals, and patterns of care delivery. Real-world insights were synthesized from clinical registries and anonymized claims narratives to illuminate treatment pathways and site-of-care transitions without relying on proprietary market sizing datasets.

Qualitative inputs were validated through cross-stakeholder discussions to reconcile clinical practice variations and to surface emergent trends in patient preferences and distribution logistics. Supply chain and tariff-related analyses drew from customs regimes, trade policy announcements, and industry operational reports to characterize plausible impacts on manufacturing and distribution. Throughout the methodology, emphasis was placed on triangulating evidence sources, documenting assumptions, and highlighting areas where data gaps warrant targeted post-market studies or registries to inform long-term strategy.

Summarizing why integrated clinical innovation, supply chain resilience, and real-world evidence are essential to translate therapeutic advances into sustained patient access

The therapeutic landscape for hereditary angioedema is at an inflection point where mechanistic innovation, administration flexibility, and new evidence paradigms converge to create differentiated care pathways. Clinicians now have a broader armamentarium to tailor interventions to individual patient needs, balancing immediate on-demand interventions against longer-term prophylactic strategies that can improve quality of life. At the same time, commercial success increasingly depends on demonstrating value beyond controlled trials-through real-world effectiveness, reduced acute care dependency, and patient-centered outcomes.

Operational resilience is equally vital: manufacturers and distributors must manage supply chain complexity, adapt to policy shifts, and ensure that evolving formulations reach patients in clinic and home settings reliably. Stakeholders who integrate clinical, logistical, and economic perspectives into a unified strategy will be best positioned to translate therapeutic advances into sustainable patient benefit and commercial viability. Ongoing collaboration across clinicians, payers, advocacy groups, and manufacturers will be essential to refine guidelines, capture meaningful outcomes, and expand equitable access to innovative therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hereditary Angioedema Therapeutics Market, by Treatment Type

  • 8.1. On Demand
    • 8.1.1. Bradykinin Receptor Antagonist
    • 8.1.2. Kallikrein Inhibitor
    • 8.1.3. Plasma Derived C1 Inhibitor
    • 8.1.4. Recombinant C1 Inhibitor
  • 8.2. Prophylaxis
    • 8.2.1. Monoclonal Antibody
    • 8.2.2. Oral Small Molecule
    • 8.2.3. Plasma Derived C1 Inhibitor

9. Hereditary Angioedema Therapeutics Market, by Drug Class

  • 9.1. Bradykinin Receptor Antagonist
  • 9.2. Kallikrein Inhibitor
  • 9.3. Monoclonal Antibody
  • 9.4. Plasma Derived C1 Inhibitor
  • 9.5. Recombinant C1 Inhibitor

10. Hereditary Angioedema Therapeutics Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Hereditary Angioedema Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Retail Pharmacies
  • 11.3. Online Pharmacies

12. Hereditary Angioedema Therapeutics Market, by End User

  • 12.1. Clinic
  • 12.2. Home Care
  • 12.3. Hospital

13. Hereditary Angioedema Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Hereditary Angioedema Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hereditary Angioedema Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Hereditary Angioedema Therapeutics Market

17. China Hereditary Angioedema Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Apellis Pharmaceuticals, Inc.
  • 18.6. Attune Pharmaceuticals, Inc.
  • 18.7. Biocryst Pharmaceuticals, Inc.
  • 18.8. BioMarin Pharmaceutical Inc.
  • 18.9. CSL Behring LLC
  • 18.10. Ionis Pharmaceuticals, Inc.
  • 18.11. KalVista Pharmaceuticals, Inc.
  • 18.12. Novartis AG
  • 18.13. Pharming Group N.V.
  • 18.14. Sanofi S.A.
  • 18.15. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 155. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 156. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 179. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 180. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 187. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 188. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)